Novak Djokovic: Acquires 80% of company developing COVID19 treatment

The company aims to begin clinical trials of its drug in the UK this summer 

novak djokovic Novak Djokovic

This is the biotechnology company QuantBioRes, which aims to start clinical trials of its drug in the UK in the summer.

The unvaccinated Novak Djokovic who was deported from Australia and does not play in the Australian Open it was revealed that he had acquired 80% of a company in Denmark that works to manufacture a drug to fight coronavirus.

According to Reuters, the Serbian tennis player has an 80% stake in the Danish biotechnology company QuantBioRes, which aims to develop medical treatment to treat Covid-19, as the CEO of the company stated in the agency.

CEO Ivan Lonkarevic, who described himself as a businessman, said the investment was made in June 2020, but declined to say how much was invested by the Serbian tennis player.

QuantBioRes has about 11 researchers working in Denmark, Australia and Slovenia, according to Lonkarevic, who emphasized that their research Covid-19 and not in a vaccine.

The company is developing a peptide that prevents the coronavirus from infecting human cells, and is expected to begin clinical trials in the UK this summer.